Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470776 | 0.85 | CYP1A2 (0.65) | CYP1A2TDP1NPSR1ALDH1A1HTR1A | |
| Hydrochloric Acid SCHEMBL15209250 | 0.83 | CYP1A2 (0.62) | CYP1A2TDP1NPSR1ALDH1A1HTR1A | |
| SCHEMBL3031054 | 0.82 | CYP1A2 (0.50) | CYP1A2TDP1ALDH1A1MAPT | |
| SCHEMBL3554732 | 0.78 | ALDH1A1 (0.62) | NPSR1ALDH1A1MAPTCA2HTT | |
| SCHEMBL5219362 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPTCA2HTTHSD11B1 | |
| SCHEMBL22273305 | 0.78 | ALDH1A1 (0.67) | CYP1A2TDP1NPSR1ALDH1A1HTR1A | |
| SCHEMBL6997610 | 0.78 | ALDH1A1 (0.70) | CYP1A2TDP1NPSR1ALDH1A1HTR1A | |
| SCHEMBL21732986 | 0.76 | CYP1A2 (0.54) | CYP1A2TDP1NPSR1ALDH1A1HTR1A | |
| SCHEMBL3437018 | 0.76 | ALDH1A1 (0.75) | CYP1A2TDP1NPSR1ALDH1A1HTR1A | |
| SCHEMBL3031399 | 0.76 | ALDH1A1 (0.67) | NPSR1ALDH1A1MAPTCA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653081-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-02-18 | — | — | US | claimed |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2013-11-07 | — | — | US | claimed |
| US-8410108-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-04-02 | — | — | US | claimed |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | claimed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-1959962-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007078815-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3897839-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126952-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-8653081-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8410108-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1959962-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007078815-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | CYP1A2 4402/4885TDP1 3263/4885NPSR1 4682/4885 |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNI3, MYLK2, TNNT2 | CYP1A2 4552/4885TDP1 3499/4885NPSR1 4725/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CYP1A2 74/4885TDP1 2111/4885NPSR1 2685/4885 |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | CYP1A2 4402/4885TDP1 3263/4885NPSR1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.